By Eli Hughes–
The cell therapy startup Koligo Therapeutics Inc. plans to test a new therapy for effectiveness in treating COVID-19. Koligo Therapeutics Inc. was founded by two U of L alumni and was recently acquired by biotech firm Orgenisis Inc.
The COVID-19 trial will focus on 75 patients and will test the cell therapy KT-PC-301’s ability to treat COVID-19 related acute respiratory distress syndrome. KT-PC-301 is a cell therapy that is taken from the patient’s own fat tissue.
A small tissue sample is taken from the patient, it is then sent to Koligo to be made into KT-PC-301.